EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Assessment of Allometric Scaling Methods for the Prediction of Human Pharmacokinetic of LNA ‐i‐ miR ‐221

Hadija Marchiori iD, Michele Schiavon iD, Chiara Roversi, Simone Zannoni, Massimiliano Fonsi, Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Teresa Di Martino, Alessia Tagliavini, Chiara Dalla Man

CPT: Pharmacometrics & Systems Pharmacology · 2026-11 · 15 (11)

DOI: 10.1002/psp4.70359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 05.11.2026. Verfasst von Hadija Marchiori und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Information Engineering, University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: MicroRNAs, Oligonucleotides, Oligonucleotides, Antisense, Models, Biological. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Association for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antisense oligonucleotides are small synthetic DNA or RNA molecules that can be used to modulate gene expression, particularly to block the production of unwanted proteins. This makes them potentially powerful drugs to contrast cancer growth. Drug development is a long process that includes preclinical and clinical studies. Preclinical animal studies are designed to assess drug kinetics and safety before progressing to clinical trials, as they may predict the therapeutic dose to be used in the “first in human” (FIH) studies. This is usually achieved by applying allometric scaling methods that allow predicting the human pharmacokinetic (PK) parameters from those estimated in animals. Selecting the appropriate scaling formula reduces the risk of translational uncertainty and supports the design of FIH studies. The aim of this study is to compare the accuracy of different allometric scaling methods in predicting human PK of the antisense oligonucleotide LNA‐i‐miR‐221, a powerful inhibitor of microRNA miR‐221, which was found to be deregulated in several malignancies, favoring cancer progression. To do that, we exploited the availability of PK data of the drug in both Sprague Dawley rats and humans and we found that the best scaling method for both clearance and distribution volume is the simple allometry, with predictions laying within the 2‐fold and 4‐fold error interval, respectively. This study contributes to identifying the most accurate scaling methods among the evaluated single‐species approaches to extrapolate human pharmacokinetic for LNA‐i‐miR‐221, possibly offering a starting point for future studies involving antisense oligonucleotides.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsOligonucleotidesOligonucleotides, AntisenseModels, BiologicalHumansAnimalsRatsRats, Sprague-DawleyMale

Stichwörter der Autor:innen

ASONLMEPKPDcancer treatment

Substanzen

MicroRNAsOligonucleotidesMIR221, humanOligonucleotides, Antisenselocked nucleic acid

Autor:innen und Institutionen

  • Department of Information Engineering, University of Padua, Padua, Italy.
  • Department of Clinical Development & Translational Medicine, Aptuit (Verona) Srl, an Evotec Company, Verona, Italy.
  • Evotec France SAS, ADME & Developability Assessment, Toulouse, France.
  • Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy.

ORCID-Profile: Hadija Marchiori, Michele Schiavon

Förderung

  • Italian Association for Cancer Research

Zitieren

APA

Marchiori, H., Schiavon, M., Roversi, C., Zannoni, S., Fonsi, M., Tassone, P., Tagliaferri, P., Di Martino, M. T., Tagliavini, A., & Dalla Man, C. (2026). Assessment of Allometric Scaling Methods for the Prediction of Human Pharmacokinetic of LNA ‐i‐ miR ‐221. CPT: Pharmacometrics & Systems Pharmacology, 15(11). https://doi.org/10.1002/psp4.70359

Vancouver

Marchiori H, Schiavon M, Roversi C, Zannoni S, Fonsi M, Tassone P, et al. Assessment of Allometric Scaling Methods for the Prediction of Human Pharmacokinetic of LNA ‐i‐ miR ‐221. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(11). doi:10.1002/psp4.70359

BibTeX
@article{Marchiori2026,
  author = {Marchiori, Hadija and Schiavon, Michele and Roversi, Chiara and Zannoni, Simone and Fonsi, Massimiliano and Tassone, Pierfrancesco and Tagliaferri, Pierosandro and Di Martino, Maria Teresa and Tagliavini, Alessia and Dalla Man, Chiara},
  title = {Assessment of Allometric Scaling Methods for the Prediction of Human Pharmacokinetic of LNA ‐i‐ miR ‐221},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/psp4.70359}
}
Kostenlos starten →